240 related articles for article (PubMed ID: 33097567)
41. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
42. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
[TBL] [Abstract][Full Text] [Related]
43. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J
Br J Cancer; 2018 Oct; 119(9):1075-1085. PubMed ID: 30353045
[TBL] [Abstract][Full Text] [Related]
44. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
[TBL] [Abstract][Full Text] [Related]
46. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
47. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Lee JM; Moore RG; Ghamande S; Park MS; Diaz JP; Chapman J; Kendrick J; Slomovitz BM; Tewari KS; Lowe ES; Milenkova T; Kumar S; Dymond M; Brown J; Liu JF
Clin Cancer Res; 2022 Oct; 28(19):4186-4193. PubMed ID: 35917514
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Yoshihama T; Kuroda Y; Chiyoda T; Takahashi M; Yoshimura T; Saotome K; Nanki Y; Sakai K; Kobayashi Y; Yamagami W; Aoki D
Int J Clin Oncol; 2022 Oct; 27(10):1644-1650. PubMed ID: 35835930
[TBL] [Abstract][Full Text] [Related]
50. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
51. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA
Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051
[TBL] [Abstract][Full Text] [Related]
52. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
[TBL] [Abstract][Full Text] [Related]
53. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
54. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
55. Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
Heo YA; Dhillon S
Target Oncol; 2018 Dec; 13(6):801-808. PubMed ID: 30456461
[TBL] [Abstract][Full Text] [Related]
56. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Lord R; Rauniyar J; Morris T; Condon O; Jones R; Miller R; Hall M; Lofts F; Glasspool RM; Hudson E
Int J Gynecol Cancer; 2020 Jul; 30(7):1026-1033. PubMed ID: 32321768
[TBL] [Abstract][Full Text] [Related]
57. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
58. Maintenance olaparib in advanced ovarian cancer.
Burki TK
Lancet Oncol; 2018 Dec; 19(12):e671. PubMed ID: 30509885
[No Abstract] [Full Text] [Related]
59. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ; Zimmer A; Padget M; Cimino-Mathews A; Nair JR; Liu Y; Swisher EM; Hodge JW; Nixon AB; Nichols E; Bagheri MH; Levy E; Radke MR; Lipkowitz S; Annunziata CM; Taube JM; Steinberg SM; Lee JM
Clin Cancer Res; 2020 Aug; 26(16):4268-4279. PubMed ID: 32398324
[TBL] [Abstract][Full Text] [Related]
60. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
